In an era bustling with advancements in human medicine, the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) plays a crucial role in ensuring drug safety across the continent. From September 29 to October 2, 2025, PRAC convened to evaluate multiple aspects of pharmacovigilance including new safety signals, variation procedures, and risk management plans. Members grappled with these multifaceted objectives to refine regulations and safeguard public health. The session, chaired by Ulla Wändel Liminga, concentrated on a plethora of pressing issues in recognition of the critical need for continual monitoring and assessment of authorized medicines within the EU.
Addressing Safety Signals and Drug Interaction Concerns
PRAC dedicated considerable attention to signals of new drug interactions, focusing on potential safety concerns arising from the use of Tirzepatide and Pancreatin. The session addressed the identified signal of interactions between Tirzepatide and warfarin, considering possible impacts on international normalized ratio levels. For Pancreatin, the committee evaluated signals related to the risk of viral infection from product use. Both instances underlined the PRAC’s ongoing commitment to the timely identification and management of potential pharmacovigilance risks to ensure patient safety across Europe.
Risk Management and Conditional Approvals in Focus
The committee also dealt with Risk Management Plans (RMPs) for preparations in both pre- and post-authorization phases. An array of medicines, from Aficamten intended for cardiac issues to Tirzepatide for diabetes, was examined for efficacy and safety profiles. Additionally, PRAC reviewed conditional marketing renewals for medications such as Belzutifan and Etranacogene dezaparvovec to determine compliance with safety strategies. The overarching aim was the incorporation of regulatory assessments into frameworks that bolster medicinal safety.
Significant inferences were made during the assessments, elucidating several high-impact areas. The recognition of viral transmission risks in Pancreatin highlights a need for stringent viral transmission control measures in production. The interaction of Tirzepatide with blood-thinning agents like warfarin points to the necessity for adjusted dosages and enhanced prescribing information for practitioners. Furthermore, the adoption of variations for immunogenic drugs reflects the agency’s proactive stance in promptly addressing patient safety and therapeutic effectiveness through rigorous pharmacokinetic evaluations.
PRAC continues to embody a formidable force in pharmacovigilance within Europe, ensuring medicines undergoing regulatory assessments meet the dynamic expectations of safety and efficacy. Transparency and robust regulatory frameworks were identified as pivotal tools in yielding nuanced assessments and expertly managing drug safety. In a global health landscape where complexities around drug interactions and patient safety are rising, the PRAC agenda embodies an indispensable mechanism in the pursuit of preserving public health through meticulous pharmacovigilance. Readers invested in patient safety and drug efficacy can find more details on specific agenda items on the EMA’s official website at www.ema.europa.eu.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
